Lundbeck to trial migraine drug in young people

A new phase III trial in the US will investigate whether extending the patient target group of Lundbeck's drug Vyepti to include younger patients is possible.

Lundbeck's headquarters in Valby, Copenhagen | Photo: Lundbeck / PR

285 participants aged 12-17 will test Lundbeck's drug Vyepti as a preventative treatment for migraines over the next year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs